Study on antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic wistar rats

Rekha M. B., Basavaraj Bhandare, S. V, Hemamalini M. B.
{"title":"Study on antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic wistar rats","authors":"Rekha M. B., Basavaraj Bhandare, S. V, Hemamalini M. B.","doi":"10.18203/2319-2003.IJBCP20212081","DOIUrl":null,"url":null,"abstract":"Background: Diabetes mellitus is a chronic metabolic disorder that develops due to insulin deficiency or insulin resistance. Recent animal and human studies have reported bromocriptine to be effective in the management of type 2 diabetes mellitus. The present study was done to evaluate the antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic rats. Methods: Male wistar rats were used and divided into 5 groups. Dexamethosone was used to induce hyperglycemia in group B-E. Group A was the untreated control group, group B was the standard control group, group C was the oral 10 mg/kg of bromocriptine dissolved in 0.9% normal saline, group D was the oral 20 mg/kg metformin dissolved in 0.9% normal saline, group E was the oral 10 mg/kg bromocriptine+20 mg/kg metformin dissolved in 0.9% normal saline. Fasting blood glucose, post prandial blood glucose and body weight was estimated on day 1, 15, 30. Results: It was seen that dexamethasone induced hyperglycemia and increase in body weight in male wistar rats, which were significantly controlled by oral bromocriptine and bromocriptine with metformin combination. Conclusions: Results obtained from this study showed that bromocriptine can be a promising drug with novel mechanism to treat type 2 diabetes mellitus.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"51 1","pages":"699"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of basic and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.IJBCP20212081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Diabetes mellitus is a chronic metabolic disorder that develops due to insulin deficiency or insulin resistance. Recent animal and human studies have reported bromocriptine to be effective in the management of type 2 diabetes mellitus. The present study was done to evaluate the antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic rats. Methods: Male wistar rats were used and divided into 5 groups. Dexamethosone was used to induce hyperglycemia in group B-E. Group A was the untreated control group, group B was the standard control group, group C was the oral 10 mg/kg of bromocriptine dissolved in 0.9% normal saline, group D was the oral 20 mg/kg metformin dissolved in 0.9% normal saline, group E was the oral 10 mg/kg bromocriptine+20 mg/kg metformin dissolved in 0.9% normal saline. Fasting blood glucose, post prandial blood glucose and body weight was estimated on day 1, 15, 30. Results: It was seen that dexamethasone induced hyperglycemia and increase in body weight in male wistar rats, which were significantly controlled by oral bromocriptine and bromocriptine with metformin combination. Conclusions: Results obtained from this study showed that bromocriptine can be a promising drug with novel mechanism to treat type 2 diabetes mellitus.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
溴隐亭对地塞米松致高血糖大鼠降糖作用的研究
背景:糖尿病是由胰岛素缺乏或胰岛素抵抗引起的慢性代谢紊乱。最近的动物和人类研究报道溴隐亭对2型糖尿病的治疗有效。研究溴隐亭对地塞米松致高血糖大鼠的降糖作用。方法:选用雄性wistar大鼠,随机分为5组。B-E组采用地塞米松诱导高血糖。A组为未治疗对照组,B组为标准对照组,C组为0.9%生理盐水中溶解溴隐亭10 mg/kg口服,D组为0.9%生理盐水中溶解二甲双胍20 mg/kg口服,E组为10 mg/kg溴隐亭+ 0.9%生理盐水中溶解二甲双胍20 mg/kg口服。测定第1、15、30天的空腹血糖、餐后血糖和体重。结果:地塞米松引起雄性wistar大鼠高血糖和体重增加,口服溴隐亭和溴隐亭联合二甲双胍可明显控制高血糖和体重增加。结论:溴隐亭具有治疗2型糖尿病的新机制,是一种很有前景的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Assessment of KaraShieldTM properties in supporting the immune health of healthy subjects: a randomized, parallel, double-blind, placebo-controlled clinical study Knowledge attitude and practices of drug promotional literature: a clinician’s perspective Evaluation of β-blockers dosage regimen rationality in heart failure patients Perceptions of undergraduate medical students of old traditional and new CBME curriculum about pharmacovigilance and adverse drug reactions reporting at a tertiary care teaching hospital: a comparative study Comparison of efficacy of azilsartan with olmesartan in patients of hypertension: randomized controlled trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1